Boston, MA 02\/19\/2014 (wallstreetpr) – JPMorgan Chase & Co. (NYSE:JPM)<\/b> is mourning the death of yet another one of its bankers. The leading U.S. lender and global banking services provider started the week with the tragic death of one of its investment banker who plunged to death from the roof of its 30-storey headquarters in Hong Kong. The bank stated in an email to media outlets that police was investigating the matter, but failed to discuss further details around the latest suicide of its global banker. The latest suicide incident comes in just a few weeks after that which involved London-based technology chief known as Gabriel Magee, 39, on January 28. Away from suicide, JPMorgan Chase & Co. (NYSE:JPM) gained 34 cents on each of its shares in the last session to settle at $58.49 per share.<\/p>\n
Gilead Sciences, Inc. (NASDAQ:GILD) <\/b>stock gained 3.2 percent in the last session to attain $83.81 per share. It was also a day that saw the stock escalate to a high of $83.98. The excitement around GILD can be seen in the recent positive study results which showed that its experimental hepatitis C drug met the clinical trial goal. The company is seemingly betting a lot on the drug and it hopes that FDA would give it an okay. Besides pointing at the efficacy of the hepatitis C drug, GILD is also talking about the possibility of reducing treatment period from the present 12 \u2013 14 weeks to just about eight weeks using its proposed drug. Patients will also incur less cost in hepatitis C treatment using the new drug. All in all, Gilead Sciences, Inc. (NASDAQ:GILD) believes that the approval of the drug will be able boost its revenue significantly.<\/p>\n
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)<\/b>: After the FDA lifted the temporary ban on the sale of leukemia drug Iclusig from ARIA, the stock has been seeing growing investor interest. The prospects are seen in the revenue opportunity brought about by Iclusig. Although the drug currently has a small market according to the latest available data showing the number of patients that could use it, the high cost of drug and its efficacy might just as well lead to significant revenue. The drug on wholesale price cost $115,000 per year per patient. Thus, analysts believe that while previous sales have been very low, there are possibilities for the drug to generate sales of $500 million a year. It is the success potential of Iclusig that has reportedly generated rumors that global biotech giants GSK, Shire and Eli Lilly might be salivating for Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) for a takeover deal.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 02\/19\/2014 (wallstreetpr) – JPMorgan Chase & Co. (NYSE:JPM) is mourning the death of yet another one of its bankers. The leading U.S. lender […]<\/p>\n","protected":false},"author":32,"featured_media":15565,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236],"tags":[2780,1978,1628,2781,1522,603],"stock_ticker":[],"class_list":["post-15564","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-ariad-pharmaceuticals-inc-nasdaqaria","tag-gilead-sciences-inc-nasdaqgild","tag-jpmorgan-chase-co-nysejpm","tag-nasdaqaria","tag-nasdaqgild","tag-nysejpm","entry"],"acf":[],"yoast_head":"\n